No Data Yet
On December 18, 2025, Daiichi Sankyo and AstraZeneca's marketing application for their cancer drug DATROWAY was validated by the EMA, targeting the 70% of metastatic triple-negative breast cancer patients ineligible for immunotherapy.
The U.S. FDA has approved a new combination therapy for HER2-positive metastatic breast cancer, positioning a treatment from AstraZeneca and Daiichi Sankyo as a new first-line standard of care. This decision is expected to significantly impact the treatment landscape and the market positions of the involved pharmaceutical companies.